Literature DB >> 18041746

Liver resection for metastases from breast cancer.

Armin Thelen1, Christoph Benckert, Sven Jonas, Enrique Lopez-Hänninen, Jalid Sehouli, Ulf Neumann, Birgit Rudolph, Peter Neuhaus.   

Abstract

BACKGROUND AND OBJECTIVES: The value of liver resection for metastases from breast cancer is still controversial. This study was conducted to clarify safety and effectiveness of hepatectomy in this conditions and to identify selection criteria for patients suitable for liver resection.
METHODS: From January 1988 to December 2006, 39 patients underwent liver resection for metastases from breast cancer. The outcome of these 39 patients was retrospectively reviewed using a prospective database. Prognostic factors for patient survival were determined by univariate and multivariate analysis.
RESULTS: None of the patients died perioperatively and the morbidity rate was 13% (n = 5). The overall 1-, 3-, and 5-year survival rates were 77%, 50%, and 42%, respectively. In the univariate analysis, metastatic manifestation prior to hepatectomy, vascular invasion and resection margin revealed statistically significant influence on survival. The multivariate analysis identified only resection margin as an independent prognostic factor for survival.
CONCLUSIONS: Liver resection should be considered in the multimodal treatment approach of patients with metastatic breast cancer. Hepatic resection can be performed with low risk and offers a chance of long-term survival. Achievement of a curative resection and less important absence of previous metastatic manifestation represent suitable criteria to select patients for liver resection. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18041746     DOI: 10.1002/jso.20911

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  23 in total

1.  Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.

Authors:  Andrew C Gordon; William J Gradishar; Virginia G Kaklamani; Avesh J Thuluvath; Robert K Ryu; Kent T Sato; Vanessa L Gates; Riad Salem; Robert J Lewandowski
Journal:  J Vasc Interv Radiol       Date:  2014-08-22       Impact factor: 3.464

2.  A comparison of laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of breast cancer metastasis to the liver.

Authors:  Yunus Taşçi; Erol Aksoy; Halit Eren Taşkın; Shamil Aliyev; Halle Moore; Orhan Ağcaoğlu; Onur Birsen; Allan Siperstein; Eren Berber
Journal:  HPB (Oxford)       Date:  2013-10       Impact factor: 3.647

Review 3.  A role for hepatic surgery in patients with liver metastatic breast cancer: review of literature.

Authors:  Nicolae Bacalbaşa; Sorin Tiberiu Alexandrescu; Irinel Popescu
Journal:  Hepat Oncol       Date:  2015-05-15

Review 4.  Improvement of survival and prospect of cure in patients with metastatic breast cancer.

Authors:  Yee Chung Cheng; Naoto T Ueno
Journal:  Breast Cancer       Date:  2011-05-13       Impact factor: 4.239

5.  Hepatic metastases from breast cancer.

Authors:  Arianna Rubino; Roberto Doci; Jean Claude Foteuh; Emanuela Morenghi; Susanna Fissi; Casimiro Giorgetta; Islam Abumalouh; Luca Di Tommaso; Leandro Gennari
Journal:  Updates Surg       Date:  2010-12

Review 6.  The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review.

Authors:  Timothy L Fitzgerald; Jason Brinkley; Shannon Banks; Nasreen Vohra; Zachary P Englert; Emmanuel E Zervos
Journal:  Langenbecks Arch Surg       Date:  2014-08-23       Impact factor: 3.445

Review 7.  The role of local therapy in the management of lung and liver oligometastases.

Authors:  Simon S Lo; Susan D Moffatt-Bruce; Laura A Dawson; Roderich E Schwarz; Bin S Teh; Nina A Mayr; Jiade J Lu; John C Grecula; Thomas E Olencki; Robert D Timmerman
Journal:  Nat Rev Clin Oncol       Date:  2011-05-24       Impact factor: 66.675

8.  The role of liver resection in patients with metastatic breast cancer: a systematic review examining the survival impact.

Authors:  Sadia Tasleem; Jarlath C Bolger; Michael E Kelly; Michael R Boland; Dermot Bowden; Karl J Sweeney; Carmel Malone
Journal:  Ir J Med Sci       Date:  2018-02-01       Impact factor: 1.568

9.  Radiofrequency thermal ablation (RFA) of hepatic metastases (METS) from breast cancer (BC): an adjunctive tool in the multimodal treatment of advanced disease.

Authors:  Andrea Veltri; Carlo Gazzera; Monica Barrera; Marco Busso; Federica Solitro; Claudia Filippini; Irene Garetto
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

10.  Aggressive treatment for hepatic metastases from breast cancer: results from a single center.

Authors:  F Polistina; G Costantin; A Febbraro; E Robusto; G Ambrosino
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.